Home › Alzheimer's Disease › NCT06104852
Triage Survey for Neurology Research Eligibility
RecruitingObservational studyHealthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Participant and study partner (when applicable) have signed an ICF prior to study-specific procedures being performed. * Participant and study partner (when applicable) are at least 18 years old. Exclusion Criteria: * Participant lacks the language skills or cognitive ability to understand the screening process. * Participant is pregnant, breast-feeding, or planning to become pregnant. * History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results. * Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on Columbia-Suicide Severity Rating Scale questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening. * Moderate or severe substance use disorder within 90 days prior to screening, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant. * Any condition that in the investigator's opinion makes a participant unsuitable for the study. * Currently employed by Adams Clinical or a first-degree relative of an employee working on this study.
About the study
TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.
What is being tested
- Survey (other)
- Optional Medication Washout (other)
Sponsor: Adams Clinical · Participants: 600 · Started: Jun 2, 2023
Contact the study team
- Sarah J Starling, PhD · Phone: 6177448542
Official record on ClinicalTrials.gov — NCT06104852
Locations in the U.S.
| Massachusetts | Copley Clinical, Boston (Not yet recruiting) Adams Clinical, Watertown |
| New York | Berman Clinical, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.